NCT03403881

Brief Summary

Randomized clinical trial that aims to increase physical activity levels in people with depression and to evaluate if the increase on PA levels has impact on clinical and biological measures.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
130

participants targeted

Target at P75+ for not_applicable major-depressive-disorder

Timeline
Completed

Started Mar 2016

Typical duration for not_applicable major-depressive-disorder

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2016

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

June 28, 2017

Completed
7 months until next milestone

First Posted

Study publicly available on registry

January 19, 2018

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2018

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2019

Completed
Last Updated

February 7, 2018

Status Verified

February 1, 2018

Enrollment Period

2.8 years

First QC Date

June 28, 2017

Last Update Submit

February 5, 2018

Conditions

Keywords

ExercisePhysical activityBehavioral changeDepressionMajor Depressive DisorderHealth promotion

Outcome Measures

Primary Outcomes (1)

  • Depressive symptoms (blinded assessment)

    Hamilton scale for depressive symptoms assessed by a blinded psychiatrist. Clinician-administered semi-structured interview with 17 questions. It is designed to measure the severity of depressive symptoms in patients with a primary depressive illness. Higher scores means higher depressive symptoms. The cutoffs are the following: following severity ranges for the HAMD: no depression (0-7); mild depression (8-16); moderate depression (17-23); and severe depression (≥24). The maximum score is 52.

    At the end of the intervention (6 months)

Secondary Outcomes (6)

  • Physical activity - self-report

    At the end of the intervention (6 months)

  • Physical activity levels - objective measure

    At the end of the intervention (6 months)

  • Quality of life

    At the end of the intervention (6 months)

  • Depressive symptoms (self-reported)

    At the end of the intervention (6 months)

  • Melancholia

    At the end of the intervention (6 months)

  • +1 more secondary outcomes

Study Arms (2)

Physical activity promotion + TAU

ACTIVE COMPARATOR

Physical activity promotion based on: * Pedometers use; * Weekly contact (telephone or face-to-face); * Contact based on a self-determination theory. TAU: Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation.

Behavioral: Physical activity promotion + TAU

Control

PLACEBO COMPARATOR

Weekly calls with general health content. TAU: Treatment as usual, which include medications. Medications were prescribed by psychiatrists not involved in the study participation.

Behavioral: Control

Interventions

Pedometer: Each patient will receive a pedometer with increasing weekly aims on number of steps during the trial. The number of steps to be achieved starts on 4.000 and increases progressively until the end of the trial. Behavioral strategy based on STD theory, and the assessment of barriers and facilitators of each patient. All patients were receiving treatment as usual

Physical activity promotion + TAU
ControlBEHAVIORAL

Weekly call on general health aspects + treatment as usual

Control

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • age: 18 - 65 years;
  • diagnosis of Major Depressive Disorder (DSM-IV), assessed by a trained psychiatrist;
  • score 7 or more in the HAM-D;
  • do not present clinical comorbidities that limit or contra-indicate the practice of physical activity;
  • be starting depression treatment at the Programa de transtorno do humor (PROTHUM) ;
  • have acess to a computer and have a facebook account;
  • be able to read and sign the consent term.

You may not qualify if:

  • present other psychiatric diagnosis such as bipolar disorder, schizophrenia or use of alcohol or other drugs;
  • be not liberated to the practice of physical exercises by the assistant psychiatrist.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

RECRUITING

Related Publications (3)

  • Schuch FB, Vasconcelos-Moreno MP, Borowsky C, Zimmermann AB, Rocha NS, Fleck MP. Exercise and severe major depression: effect on symptom severity and quality of life at discharge in an inpatient cohort. J Psychiatr Res. 2015 Feb;61:25-32. doi: 10.1016/j.jpsychires.2014.11.005. Epub 2014 Nov 21.

    PMID: 25439084BACKGROUND
  • Stubbs B, Vancampfort D, Rosenbaum S, Ward PB, Richards J, Ussher M, Schuch FB. Challenges Establishing the Efficacy of Exercise as an Antidepressant Treatment: A Systematic Review and Meta-Analysis of Control Group Responses in Exercise Randomised Controlled Trials. Sports Med. 2016 May;46(5):699-713. doi: 10.1007/s40279-015-0441-5.

    PMID: 26707338BACKGROUND
  • Schuch FB, Vancampfort D, Richards J, Rosenbaum S, Ward PB, Stubbs B. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. J Psychiatr Res. 2016 Jun;77:42-51. doi: 10.1016/j.jpsychires.2016.02.023. Epub 2016 Mar 4.

    PMID: 26978184BACKGROUND

MeSH Terms

Conditions

Depressive Disorder, MajorMotor ActivityDepression

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental DisordersBehaviorBehavioral Symptoms

Study Officials

  • Marcelo B Fleck, PhD

    Researcher

    STUDY DIRECTOR

Central Study Contacts

PhD

CONTACT

Felipe Schuch, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 28, 2017

First Posted

January 19, 2018

Study Start

March 1, 2016

Primary Completion

December 1, 2018

Study Completion

May 1, 2019

Last Updated

February 7, 2018

Record last verified: 2018-02

Locations